Is Abbott Laboratories (ABT) Undervalued?
The traditional Graham Number cannot be calculated for Abbott Laboratories (ABT) due to missing data. Consider using DCF or other valuation methods for a complete picture.
Analysis updated March 6, 2026
ABT Key Valuation Metrics
| Metric | Value | Signal |
|---|---|---|
| Current Price | $110.18 | — |
| Graham Number | N/A | — |
| P/E Ratio | N/A | Unprofitable |
| P/B Ratio | N/A | — |
| DCF Fair Value | N/A | — |
| Dividend Yield | 2.18% | — Moderate |
| 52-Week Range | $105.27 – $139.15 | Near 52-week low |
| Market Cap | N/A | Micro Cap |
| Sector | Healthcare | — |
How We Calculated ABT's Graham Number
The Graham Number, developed by Benjamin Graham (the father of value investing), estimates a stock's maximum fair price based on its earnings and book value.
Graham Number = √(22.5 × EPS × BVPS)
For Abbott Laboratories (ABT):
- Earnings Per Share (EPS): N/A
- Book Value Per Share (BVPS): N/A
ABT Dividend Profile
Abbott Laboratories currently pays a quarterly dividend of $0.60 per share, yielding 2.18% at the current price.
| Annual Dividend | $2.40 |
| Dividend Yield | 2.18% |
| Payout Ratio | N/A |
| Consecutive Years Paid | 0+ years |
| 5-Year Dividend Growth | N/A |
| Payment Frequency | Quarterly |
👑 Abbott Laboratories is a Dividend Aristocrat — it has increased its dividend for 25+ consecutive years.
ABT Value Score: 1/10
Our proprietary value score rates Abbott Laboratories a 1 out of 10, placing it in the “Overvalued / Caution” category for value investors.
Score Components
Graham Number not available
P/E not available
P/B not available
DCF value not available
Solid 2.2% yield
Weak balance sheet metrics
Score methodology: How We Score Stocks
Stocks Similar to ABT
These Healthcare stocks have similar valuation profiles to Abbott Laboratories:
Frequently Asked Questions About ABT
Is ABT undervalued right now?
Based on Graham Number analysis, ABT does not appear significantly undervalued as of March 6, 2026. The Graham Number of $N/A compared to the current price of $110.18 indicates a N/A% difference.
What is Abbott Laboratories's intrinsic value?
Using our DCF model, Abbott Laboratories's estimated intrinsic value is $N/A per share. The Graham Number suggests a fair value of $N/A.
What is the Graham Number for ABT?
The Graham Number for ABT is $N/A, calculated using EPS of $N/A and Book Value Per Share of $N/A. The formula is sqrt(22.5 x EPS x BVPS).
Does ABT pay a dividend?
Yes, ABT pays dividends with a yield of 2.18%. The annual dividend is $2.40 per share. It has paid dividends for 0+ consecutive years.
Is ABT a good buy right now?
Our value score rates ABT a 1/10. The stock is in the "Overvalued / Caution" category. However, this is analysis — not financial advice. Consider your own risk tolerance, portfolio allocation, and investment timeline before making any decisions.
Start Analyzing ABT Today
Ready to invest in Abbott Laboratories? Open a free brokerage account and start trading ABT with $0 commissions.
We may earn a commission when you open an account through our links. This does not affect our analysis or ratings.
Learn More About Value Investing
Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- DCF Calculator — Run your own discounted cash flow analysis
- Stock Screener — Filter stocks by value metrics
Related Articles
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecologi...
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions. Data sourced from Financial Modeling Prep API and may be delayed. Last updated: March 6, 2026.